Skip to content

The effect of topical insulin and liothyronine on the healing of foot ulcer

The effect of topical insulin and liothyronine on the healing of foot ulcer in patients with type 2 diabetes

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190810044500N20
Enrollment
78
Registered
2021-08-22
Start date
2021-09-06
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic foot ulcer. Type 2 diabetes mellitus with foot ulcer

Interventions

Intervention 1: Intervention group: Patients use topical liothyronine 0.75% cream twice a day for 12 weeks. Intervention 2: Intervention group: Patients use a combination topical cream of liothyronin

Sponsors

Yazd University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients over the age of 18 with a history of type 2 diabetes and hemoglobin A1C less than 10% Adequate literacy to fill the consent form, comprehension study Diabetic foot ulcer

Exclusion criteria

Exclusion criteria: Gangrene of the foot Osteomyelitis Severe sepsis History of alcohol consumption or substance abuse History of chronic diseases such as cancers or congestive heart failure, ESRD, liver failure Concomitant use of drugs that can adversely affect the wound healing process: glucocorticoids, immunosuppressive drugs, cytotoxic drugs Failure to sign a written consent Pregnant and lactating women Patients taking atrovastatin Patients with a history of steroid, cytotoxic or immunosuppressive drugs

Design outcomes

Primary

MeasureTime frame
Percentage of wound closures 1 to 4 per week. Timepoint: Screening phase (7 days perior to drug administration in terms of entery criteria), treatment (day zero to 4 weeks), and follow-up phase (2 and 3 months). Method of measurement: REEDA score (3-0).;Re-epithelialization. Timepoint: Screening phase (7 days perior to drug administration in terms of entery criteria), treatment (day zero to 4 weeks), and follow-up phase (2 and 3 months). Method of measurement: REEDA score (3-0).

Secondary

MeasureTime frame
The severity of the pain. Timepoint: Examination from 7 days before prescribing the drug in terms of entry criteria, treatment (day zero to 4 weeks), and phase follow-up (2 and 3 months). Method of measurement: Basal Visual analogue Scale (VAS) criterion.;Occurrence of side effects. Timepoint: At the end of the study. Method of measurement: Based on Morisky medication adherence scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFateme pasande

Yazd University of Medical Sciences

Pasandeelham73@gmail.com+98 35 3820 3419

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026